Hi, I'm CNBC producer Katie Kramer, one of the voices behind the CNBC podcast SquawkPod.

In these times of uncertainty, we want to make sure we're bringing you, our listeners, as much information as possible, as quickly as we can.

That's why we're sharing with you now as CNBC special report, Markets and Turmoil.

Listen in.

Good evening. I'm Scott Wapner on day 142 of the coronavirus crisis.

Questions tonight about Moderna's vaccine, send stocks lower.

But there are new signs tonight the country is getting back to business.

Follow the session for stocks today.

Stocks lose ground.

It's just too early to assess how well it is working.

This, as yesterday's star, becomes today's goat, shares of Moderna tanking.

Why is it that the federal government should be the source of this money?

Plus, is America turning against our cities? As more companies allow working from home,

what's the downside? This CNBC special report, markets in turmoil, starts right now.

Here's Scott Wapner. Welcome, good to have you with us on this Tuesday night. After a late-day sell-off,

let's get you your first look at futures tonight. It was a sudden sell-off late in the day right now,

though we are green across the board quite early, as you know. Stock closing at their lows,

following a report by our partners at Stat News, raising questions about trial results from

Moderna's vaccine candidate. The Dow and S&P 500, both falling more than 1%. The headline from

Statenews that shook the markets today, vaccine experts say Moderna didn't produce data critical

to assessing COVID-19 vaccine. For more on that report from Statt News that did move the

stock market, we are joined once again tonight by Dr. Scott Gottlieb. He is a CNBC contributor,

...